Live Breaking News & Updates on Mary Pak

Stay updated with breaking news from Mary pak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innovative Payment Models for Gene Therapies

Kimberly C. Chen, DO, MSHLM, discusses subscription models and warranties for cell and gene therapies, exploring their impact on patient access and financial sustainability. ....

Mary Pak , Ryan Haumschild , Emma Ciafaloni , Kimberlyc Chen , Peer Exchange , Jessica Nance ,

Enhancing Collaboration for Patient-Centered Care in Rare Diseases

A panel of experts discuss improving collaboration between health systems and managed care organizations to ensure optimal outcomes for patients with rare diseases. ....

Emma Ciafaloni , Kimberlyc Chen , Mary Pak , Ryan Haumschild , Peer Exchange , Jessica Nance , Gene Therapy , Managed Care , Patient Access , Clinical Data , Rare Diseases , Treatment Options , Ethical Implications , Cost Effectiveness , Coverage Determinations , Clinical Evidence , Patient Population , Financial Sustainability , Subscription Models , Warranty Programs , Performance Based Contracts , Value Based Contracting , Patient Advocacy , Research And Development , Innovative Therapies , Data Sharing ,

Ethical Implications of Patient Access Restrictions

Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control. ....

Kimberlyc Chen , Emma Ciafaloni , Ryan Haumschild , Mary Pak , Peer Exchange , Jessica Nance , Gene Therapy , Managed Care , Patient Access , Clinical Data , Rare Diseases , Treatment Options , Ethical Implications , Cost Effectiveness , Coverage Determinations , Clinical Evidence , Patient Population , Financial Sustainability , Subscription Models , Warranty Programs , Performance Based Contracts , Value Based Contracting , Patient Advocacy , Research And Development , Innovative Therapies , Data Sharing ,

Interpreting Clinical Data to Guide Coverage Decisions for Rare Disease Therapies

Health care professionals discuss the challenges related to developing and interpreting clinical data for rare disease therapies to guide payer coverage decisions. ....

Mary Pak , Ryan Haumschild , Emma Ciafaloni , Kimberlyc Chen , Peer Exchange , Jessica Nance ,

Coverage of Gene Therapies: Balancing Cost, Clinical Impact, and Durability of Effect

Ryan Haumschild, PharmD, MS, MBA, leads a discussion on factors that influence coverage of non-oncology gene therapies, exploring the balance between long-term cost savings and high initial prices, patient selection, and the durability of effect for these therapies. ....

Kimberlyc Chen , Emma Ciafaloni , Mary Pak , Ryan Haumschild , Peer Exchange , Jessica Nance , Gene Therapy , Managed Care , Patient Access , Clinical Data , Rare Diseases , Treatment Options , Ethical Implications , Cost Effectiveness , Coverage Determinations , Clinical Evidence , Patient Population , Financial Sustainability , Subscription Models , Warranty Programs , Performance Based Contracts , Value Based Contracting , Patient Advocacy , Research And Development , Innovative Therapies , Data Sharing ,